Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in Treating Recurrent or Refractory Wilms Tumor and Other Pediatric Solid Tumors
NCT05985161Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2023
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor, sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2023; status: recruiting.
02
Drugs
selinexor
Beyond the preview
Go deeper on NCT05985161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05985161.